Find your next paid study

Arizona State UniversityNCT06896825

Actual pay is set by the research site.

Low Grade GliomaMalignant Brain GliomaMalignant Brain Neoplasm+1 more

Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)

This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a…

Emory UniversityNCT06132685

~$75 – $2,000

Actual pay is set by the research site.

Observational

Reestablishing Sleep and Circadian Alignment in Medically Critically Ill Patients Via a Mechanistic Randomized Controlled Trial (RCT) of an Intensive Care Unit (ICU) Sleep Chronobundle

More than 5 million patients are admitted to the intensive care unit every year in the United States; most of these patients experience profound sleep and circ…

Critical IllnessSleep DeprivationCircadian Rhythm Sleep Disorder, Unspecified

Yale UniversityNCT05551325

Actual pay is set by the research site.

Observational

Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation Randomized Trial (STORY-AF Trial)

The overall goal of this study is to evaluate the effectiveness of a previously developed storytelling intervention on anticoagulation (AC) initiation/persiste…

Atrial FibrillationAtrial FlutterAdherence, Medication+4 more

University of Massachusetts, WorcesterNCT05997914

Actual pay is set by the research site.

Advanced Fallopian Tube CarcinomaAdvanced Fallopian Tube High Grade Serous AdenocarcinomaAdvanced Ovarian Carcinoma+15 more

MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)

This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopi…

Non-muscle-invasive Bladder Cancer

~$75 – $2,000

Predicting Outcomes in Intermediate and High-risk Non-muscle Invasive Bladder Cancer Using Automated Analysis of Digital Pathology Data

This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness t…

University of Texas Southwestern Medical CenterNCT05825950

Actual pay is set by the research site.

Phase 1

BLINKB-ALL: BLinatumomab and iNKT in Relapsed B-Cell ALL

This is an open-label, single-arm pilot study evaluating agenT-797, an invariant natural killer T-cell (iNKT) therapy, in combination with routine clinical car…

B-Cell ALLALL (Acute B-Lymphoblastic Leukemia)Philadelphia Chromosome-Negative Lymphoblastic Leukemia+1 more

UNC Lineberger Comprehensive Cancer CenterNCT07869368

~$150 – $3,000

Actual pay is set by the research site.

Phase 1

IIT2023-07-Osipov-CXCR4: Phase I Dose Escalation and Dose Expansion Study of Combination Immunotherapy With Cosibelimab and CXCR4 Inhibition With Balixafortide in Metastatic Treatment Refractory Pancreatic Ductal Adenocarcinoma

This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafo…

Metastatic Pancreatic Ductal Adenocarcinoma

Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more

~$150 – $4,500

Actual pay is set by the research site.

Arsen OsipovNCT06981806

Phase 3

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemothera…

Genelux CorporationNCT05281471

~$50 – $2,100

Actual pay is set by the research site.

Advanced Hodgkin LymphomaClassic Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8+1 more

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma

This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deox…

University of WashingtonNCT06745076

~$75 – $2,000

Actual pay is set by the research site.

Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site

A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). …

University of California, San FranciscoNCT05746208

~$75 – $1,800

Actual pay is set by the research site.

International Pediatric Adrenocortical Tumor Registry

This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumo…

Adrenocortical Tumor